Evaluation of mexiletine clearance in a Japanese population

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 241-245

  Ueno, Kazuyuki ^a   Tamamura, Akira ^b   Matsumoto, Kana ^c   Komamura, Kazuo ^b   Kamakura, Shiro ^b   Miyatake, Kunio ^b   Shibakawa, Masahiko ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Research Institute   (United States)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clearance; CYP1A2; CYP2D6; Disposition; Metabolites; Mexiletine

Indexed keywords

2 HYDROXYMEXILETINE; 4 HYDROXYMEXILETINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DRUG METABOLITE; MEXILETINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG SCREENING; FEMALE; HEART DILATATION; HEART VENTRICLE ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, DILATED; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; JAPAN; MALE; MEXILETINE; MIDDLE AGED;

EID: 0036164029     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10188     Document Type: Article

References (31)

1. A classification of antiarrhythmic actions reassessed after a decade of new drugs
2. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine
3. Mexiletine: A review of its pharmacological properties and therapeutic efficacy in arrhymias
4. The clinical pharmacology of mexiletine
5. Clinical pharmacokinetics of mexiletine
6. Absorption, distribution and elimination of mexiletine
7. Mexiletine metabolism in vitro by human liver
8. Stereoselective disposition of mexiletine in man
9. The distribution, metabolism and excretion of mexiletine in man
10. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man
11. Stereoselective hydroxylation of mexiletine in human liver microsomes: Implication of P450 IID6 - A preliminary report
12. Relative potency of mexiletine, lidocaine, and tocainide as inhibitors of rat liver CYP1A1 activity
13. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2
14. Involvement of CYP1A2 in mexiletine metabolism
15. Oral mexiletine-theophylline interaction
16. Interaction between theophylline and mexiletine
17. Mechanism of interaction between theophylline and mexiletine
18. Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers
19. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and caucasian populations
20. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population
21. Effect of cigarette smoking on mexiletine kinetics
22. Effect of rifampicin treatment on the kinetics of mexiletine
23. Enhanced metabolism of mexiletine after phenytoin administration
24. Improved liquid-chromatographic determination of mexiletine, an antiarrhythmic drug, in plasma
25. Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination
26. Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population
27. Investigation on the pharmacokinetics of propafenone
28. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D genes
29. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine
30. Effects of age on the pharmacokinetics of mexiletine
31. Pharmacokinetics of mexiletine in the elderly